Urodynamix Raises $1.9 Million from Exercise of Warrants

VANCOUVER, British Columbia, July 25, 2007 - Urodynamix Technologies Ltd. (TSX-V:URO) today announced that 94% of the share purchase warrants issued as part of a warrant incentive program completed in July 2006 have been exercised.  As a result of the exercise of these warrants, the Company received total cash proceeds of $1,854,100.

“We view the exercise of these warrants as a strong vote of confidence in the Company’s recent execution and excellent prospects,” said Barry Allen, President and Chief Executive Officer. “With this funding complete, Urodynamix is heading toward a major inflection point in 2007 in terms of achieving key milestones and launching important new products in North America and Europe.”

Urodynamix currently has outstanding 76,976,588 common shares, 4,616,305 warrants and 6,909,000 incentive stock options.

About Urodynamix Technologies Ltd.

Urodynamix is developing a portfolio of non-invasive diagnostic products for a variety of large and growing global markets. The Company is currently developing NIRS applications for urological conditions in men and women, intra-abdominal hypertension and compartment syndrome, erectile dysfunction and vascular diseases. The Company’s disruptive technology has the potential to affect the diagnosis and treatment of more than 200 million people worldwide.

On behalf of the Board,

“Barry Allen”
President & CEO
Urodynamix Technologies Ltd.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Craig Pamplin, PhD, CFA
Director, Corporate Development and Communications
Urodynamix Technologies Ltd.
Tel: (604) 638-0247
Email: cpamplin@urodynamix.com
www.urodynamix.com